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MART-1- and gp100-Expressing and -Non-Expressing
Melanoma Cells Are Equally Proliferative in Tumors
and Clonogenic In Vitro
Mariana Aris1,2, Mariana Rodrı´guez Zubieta1,5, Marina Colombo1,5, Juan Martı´n Arriaga2, Michele Bianchini2,
Myriam Alperovich3, Alicia I. Bravo4, Marı´a M. Barrio2 and Jose´ Mordoh1,2
MART-1 and gp100 are prototypical melanoma antigen (Ag), but their clinical use as vaccines or as targets of
cytotoxic lymphocytes achieved modest success. Possible explanations could be that as MART-1 and gp100 are
melanocyte differentiation Ag, clonogenic Ag-non-expressing cells would be spared by immune effectors,
or that clonogenic cells would be intrinsically resistant to cytotoxic lymphocytes. We therefore analyzed
the proliferative status of MART-1/gp100-expressing and -non-expressing cells in biopsies, and the clono-
genicity and sensitiveness to cytotoxic lymphocytes of the human cutaneous melanoma cell lines MEL-XY1
and MEL-XY3. Analysis of MART-1/gp100 and Ki-67 expression in 22 melanoma tumors revealed that MART-1/
gp100-expressing and -non-expressing cells proliferated competitively. MART-1, gp100, tyrosinase, and CD271
expression were studied in MEL-XY1 and MEL-XY3 colonies. At 7 days, colonies displayed positive, negative,
and mixed expression patterns. By 14 days, colonies of different sizes developed, showing cells with different
clonogenic potential, and Ag were downregulated, suggesting Ag plasticity. Subcloning of MEL-XY1 colonies
showed that Ag expression varied with time without interfering with clonogenicity. Finally, clonogenic,
MART-1/gp100-expressing cells were lysed by specific CD8 lymphocytes. Thus, MART-1 and gp100 expression
and plasticity would not interfere with proliferation or clonogenicity, and clonogenic cells may be lysed by
cytotoxic lymphocytes.
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INTRODUCTION
Cutaneous melanoma (CM) is the tumor with the fastest
growing incidence (Jemal et al., 2010). Its sequential growth
stages encompass radial and vertical growth (Clark et al.,
1989). Once the vertically growing phase is reached, CM
increases the risk of metastasis, in which case only a minority
of the patients may be cured (Edge and Compton, 2010).
Although CM is sensitive to immunological manipulations,
the nature of such sensitivity is unknown, being perhaps due
to the expression of early melanocyte differentiation antigens
(MD-Ags), such as MART-1 (Coulie et al., 1994; Kawakami
et al., 1994a) and gp100 (Kawakami et al., 1994b); late
MD-Ag such as tyrosinase (Brichard et al., 1993), tyrosinase-
related protein-2 (Wang et al., 1996), MELOE-1 (Godet
et al., 2008), or a group of cancer-testis Ag such as the
MAGE superfamily (van der Bruggen et al., 1991) and NY-
ESO-1 (Chen et al., 1997). Vaccination with MD-Ag-derived
peptides has been extensively tried in CM patients, so far with
little success (Bins et al., 2007; Hodi et al., 2010). Although
vaccination might be useful in the adjuvant setting, where
a favorable CD8 lymphocyte/tumor cell ratio might be
reached, the mechanisms of resistance to immune effectors
are poorly understood. One possibility is that MD-Ag-
expressing cells have only limited proliferation, thus allowing
putative MD-Ag-non-expressing clonogenic cells (CCs) to
survive immune effectors and repopulate the tumor (Maeurer
et al., 1996). This is especially relevant as it was recently
reported that CM-initiating cells would be defined by the
neural crest stem cell marker NGFR/CD271, and would lack
MD-Ag tyrosinase, MART-1, and gp100 (Boiko et al., 2010).
CM stem cells defined by ABCB5 also did not express MART-
1 (Schatton et al., 2010). In opposition, it was reported that
one-fourth of the CM cells were able to develop tumors in
NOD/SCID Il2rg/ mice, suggesting that a large part of CM
cells are tumorigenic per se (Quintana et al., 2008). Recently,
phenotypic Ag plasticity, including CD271 and ABCB5
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markers, was described as a source of heterogeneity in
tumorigenic CM cells (Quintana et al., 2010). In addition,
JARID1B histone demethylase was found to sustain tumor-
igenicity in CM and can reversibly turn on and off (Roesch
et al., 2010). Another escape strategy that has so far received
little attention is the possible existence of intrinsic mechan-
isms of resistance of CCs to lysis by cytotoxic T lymphocytes
(CTLs) (Rasmusson et al., 2007; Ghannam et al., 2010;
Schatton et al., 2010).
One of the objectives of this work was to study the
relationship between MD-Ag expression by CM cells and
their ability to proliferate. We have chosen MD-Ag MART-1
and gp100 as in HLA-A0201 patients, most tumor-infiltrating
lymphocytes are directed against them (Robbins et al., 2004;
Rosenberg and Dudley, 2004), thus appearing to be among
the most frequent tumor regression Ag. We analyzed MART-1
plus gp100 (MART-1/gp100) and Ki-67 expression in 22
primary and metastases biopsies; MART-1, gp100, tyrosinase,
and CD271 expression in in vitro-developed colonies, and
sensitivity of CCs to specific CTL clones.
RESULTS
Simultaneous detection of MART-1, gp100, and Ki-67 in
primary and metastatic CM
One of our aims was to study the proliferation rates of the
MART-1 and gp100-expressing and -non-expressing popula-
tions. Our tumor sample (n¼ 22) was composed of 15 thick
CM primary tumors and 7 lymph node metastases (Supple-
mentary Table S1 online). We chose thick primary CM
as, owing to their longer time of evolution, they are parti-
cularly useful to analyze the spontaneous appearance of
diverse subpopulations. Besides, melanin is progressively lost
as the tumor grows vertically, and immunohistochemistry
(IHC) is easier to interpret. A previous analysis performed
on 18 human CM cell lines and 105 benign and malign
melanocytic lesions showed that MART-1 and gp100 are
generally, but not always, coexpressed (de Vries et al., 1997).
In our tumor sample, we verified that MART-1 and gp100
were expressed in the same tumor areas, and thus they
could be determined simultaneously (data not shown).
We analyzed MART-1/gp100 and Ki-67 in the same slides.
In most tumors, heterogeneous populations were observed,
and for each biopsy qualitatively different areas were
delineated on the basis of tissue architecture, cellular
features, the presence of melanin, and Ag expression
patterns. Areas with the absence of melanin were chosen to
quantify IHC. Illustrative results from patient #10 showed
areas without defined structures (Figure 1a, b and g, h),
and areas (Figure 1c and e) with cellular nodules deli-
mited by extracellular matrix, with diverging Ag expression
(Figure 1d vs.1f). Ki-67-expressing and -non-expressing cells
could be easily distinguished in MART-1/gp100-expressing
and -non-expressing cells (Figure 1i).
Analysis of MD-Ag and Ki-67 expression in tumor samples
revealed that MD-Ag-expressing prevailed over -non-expres-
sing populations, both in primary and metastatic tumors
(13/15 patients; Po0.05; Figure 1j; Supplementary Table S2
online). No significant differences were found between
proliferative indexes of MD-Ag-expressing (PI1) and MD-Ag-
non-expressing (PI2) sub-populations, neither in primary
tumors nor in metastases. In addition, no differences were
found in PI1, PI2, or total PI between primary tumors and
metastases (Figure 1j, Supplementary Table S2 online). There-
fore, the expression of MART-1 and gp100 is not associated
with a diminished proliferative potential of melanoma cells.
Expression of MART-1, gp100, and tyrosinase MD-Ag by CCs
We demonstrated that the proliferative rate of melanoma
cells is not affected by the expression of MART-1 and gp100.
However, proliferation in vivo may be found not only in CCs
but also in cells already committed to full differentiation
(Ballare et al., 1991). Therefore, to investigate the relationship
between MART-1, gp100, and clonogenicity, we studied
these Ag in colonies developed in semisolid medium
(Hamburger, 1987). Several attempts were performed to
grow colonies directly from freshly excised metastatic
lesions, but the number of developing colonies was too low
to perform any meaningful analysis. We therefore resorted to
the use of CM cell lines (von Euw et al., 2007). MEL-XY1 was
derived from a lung metastasis (PI 16.7%) and presented a
heterogeneous pattern of MART-1 and gp100 expression,
similar to the original tumor (Figure 2a and b). Culture of
isolated cells under anchorage-independent conditions gave
rise by 7 days to colonies with compact morphology, with
around 100 cells each (Figure 2c). At a later stage (14 days),
colonies of different sizes developed, the larger colonies
containing thousand cells and presenting central cores with
necrotic cells (Figure 2d). Analysis by Annexin V/propidium
iodide staining on CCs purified from 7-day colonies showed
10% of apoptotic/necrotic cells. Surprisingly, 14-day CCs
revealed that only 1% of the cells were necrotic/apoptotic
and 5.6% were necrotic (Supplementary Figure S1a online).
Thus, most of the necrotic central cells histologically
observed (Figure 2d) probably disintegrated during the
purification protocol. It should be mentioned that hetero-
geneity in 14-day colony sizes suggests that cells with
differential clonogenic potential coexist in MEL-XY1 cell line.
Analysis of MART-1 and gp100 in MEL-XY1 7-day colonies
revealed a heterogeneous expression pattern (Figure 2c, g,
h, and i), with most cells being Ki-67þ (Figure 2e and j).
Gp100-non-expressing colonies (42%) were almost twice
that of MART-1-non-expressing colonies (21%), and, as
expected, simultaneous detection of both MD-Ag resulted
in a lower number of non-expressing colonies (Figure 2k–m).
In 14-day colonies, with Ki-67þ cells peripheral to necrotic
centers, the proportion of MART-1, gp100, and MART-1/
gp100-expressing colonies decreased, suggesting MD-Ag
downregulation with time (Figure 2k–m). No differences
were found in MD-Ag expression in 14-day colonies
regardless of their size (t-test P40.05, data not shown).
MART-1 and gp100 FACS analysis performed on CCs isolated
from purified colonies also showed a decrease in the intensity
and percentage of Ag-expressing cells, supporting IHC results
(Figure 2n–p).
MEL-XY3, a cell line derived from a patient’s lymph node
metastasis (PI 11.4%), expressed these MD-Ag homogeneously,
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similar to the biopsy of origin (Supplementary Figure S2a, b
online). By 7 days, MEL-XY3 colonies expressed MART-1/
gp100 homogenously and were highly proliferative (Supple-
mentary Figure S2c, e online). By 14 days, there were also
colonies of different sizes, some of them with necrotic cores
and Ki-67þ peripheral cells (Supplementary Figure S2d, f
online); MD-Ag downregulation was also observed (Supple-
mentary Figure S2g–i online). Less than 10% of the cells were
apoptotic/necrotic by Annexin V/propidium iodide staining
(Supplementary Figure S1b online). No differences in MD-Ag
expression in late-stage colonies were found regardless of
their size (t-test P40.05, data not shown).
Tyrosinase expression was also determined in 7-day and
14-day colonies in both cell lines. For MEL-XY1, most 7-day
colonies presented a mixed-expression pattern (Figure 3a–c).
In 14-day colonies, tyrosinase downregulation was observed.
For MEL-XY3, tyrosinase expression was observed mainly at
the periphery of mixed-pattern colonies, and by 14 days Ag-
expressing colonies were absent (Supplementary Figure S3a–c
online).
Altogether, these findings further support that MD-Ag
expression exhibits considerable plasticity with growth time.
Expression of CD271 in CCs
As CD271 was reported as a stem cell marker in melanoma
(Boiko et al., 2010), we analyzed its expression in CCs. In
MEL-XY1 and MEL-XY3 colonies, CD271 was barely
detectable in plasma membrane, but a strong signal was
detected in the cytoplasm (Figure 3d, Supplementary Figure
S3d online); similar results were obtained by FACS (Figure 3j
and k, Supplementary Figure S3g, h online). The Mab clone
used properly labeled the hair follicle outer root sheath cells
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Figure 1. Histological patterns, MART-1 plus gp100 (MART-1/gp100) expression, and Ki-67 expression in melanoma biopsies. Hematoxylin and eosin
(a, c, e, g) and melanocyte differentiation antigen (MD-Ag) plus Ki-67 (b, d, f, h, i) staining was performed (illustrative results from patient #10). Areas with
low expression of MD-Ag and Ki-67 (a, b), low MD-Ag and high Ki-67 expression (c, d), high MD-Ag and low Ki-67 expression (e, f), and heterogeneous
MD-Ag expression and Ki-67 cells (g–i) are shown. Examples of expression patterns: (i) MD-Ag(þ )Ki-67(þ ) cells (thick arrow), MD-Ag(þ )Ki-67() cells
(thin arrow), MD-Ag(-)Ki-67(þ ) cells (dotted arrow), and MD-Ag()Ki-67() cells (arrowhead). Bar¼ 10mm (a–h); 5mm (i). (j) MART-1/gp100 expression
and proliferative index (PI)1, PI2, and total PI of the 22 analyzed tumors are shown as median percentage and range. ns, no significant differences were
found (Wilcoxon test, P40.05).
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and dermal nerves in normal skin as described (Inoue et al.,
2009; Figure 3g–i). As it relates to CD271 expression over
time, MEL-XY1 7-day colonies (Figure 3d–f) and MEL-XY3
7-day colonies (Supplementary Figure S3 online) showed a
heterogenous pattern, with Ag expression sharply diminishing
in 14-day colonies. These results reveal that CD271, a
putative melanoma stem cell marker, also exhibits plasticity.
Plasticity of MART-1 and gp100 in melanoma clones
We were interested in determining whether MD-Ag-non-
expressing colonies arose from Ag-non-expressing CCs or
from Ag-expressing CCs that changed their phenotypic
pattern after division and differentiation. FACS sorting
of viable Ag-expressing and -non-expressing cells is not
possible, as to perform immunodetection of MART-1/gp100
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Figure 3. Tyrosinase and CD271 expression in MEL-XY1 colonies. Tyrosinase expression in 7-day colonies is heterogeneous, prevailing a peripheral
mixed staining pattern (a, c), diminishing by 14 days (b, c). CD271 expression in 7-day colonies is heterogeneous, being mainly intracellular (d, f). The 14-day
colonies show antigen (Ag) downregulation (e, f). Results are expressed as mean±SD of two independent experiments. Positive controls used for CD271
expression are hair follicles (g, h) and nerves in normal skin (i). Representative histograms of CD271 FACS analysis with percentage of expressing cells are shown
(j, k), revealing CD271 intracellular expression and Ag downregulation by 14 days. Gray-filled histogram: isotype-matched control; orange-filled histogram:
7-day colonies; black line: 14-day colonies. *t-test (c, f) and Kolmogorov–Smirnov test (j, k), Po0,05. Bar¼20 mm (a, d, g–i); 50 mm (b, e).
Figure 2. Histological patterns, MART-1 plus gp100 (MART-1/gp100) expression, and Ki-67 expression in MEL-XY1 colonies. MART-1/gp100 expression
is heterogeneous in biopsy (a) and derived cell line, MEL-XY1 (b). 7-Day colonies have positive, negative, or mixed expression patterns (c, g–i), with
most cells being Ki-67þ (e, j). The 14-day colonies are heterogeneous in melanocyte differentiation antigen (MD-Ag) expression (d), with Ki-67þ cells
on periphery (f). Analysis of MART-1, gp100, and MART-1/gp100 expression, comparing 7- and 14-day colonies (k–m). Results are expressed as mean±SD
of two independent experiments. Representative histograms of FACS analysis with percentage of expressing cells are shown (n–p). Gray-filled histogram:
isotype-matched control; orange-filled histogram: 7-day colonies; black line: 14-day colonies. *t-test (k–m) and Kolmogorov–Smirnov test (n–p), Po0.05.
Bar¼10 mm (a, b, g–j); 20 mm (c, e); 50 mm (d, f).
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cells must be first permeabilized and cell viability would be
lost. Therefore, we resorted to cloning of CC from colonies to
investigate whether pure Ag-expressing and -non-expressing
clones could be obtained and determine whether they
regenerated a mixed population or retained their original
characteristics. We isolated 81 MEL-XY1 clones, expanded
them, and performed FACS analysis of MD-Ag expression.
We found in these clones different levels of MART-1 and
gp100 expression (Supplementary Table S3 online). No
correlation was found between MART-1 and gp100 levels
in most clones analyzed, indicating independence of gp100
expression from MART-1. We analyzed MD-Ag expression
at different times in some clones to verify Ag levels, and
we found Ag plasticity, either up- or downregulating Ag
expression, without affecting clonogenicity (Figure 4). These
results further support MART-1 and gp100 plasticity and
independence from melanoma growth.
Plasticity of MART-1 expression may be due to promoter
methylation
As early MEL-XY1 CCs variably express MART-1, whereas 7-
day MEL-XY3 CCs express this Ag uniformly, we investigated
by quantitative methylation-specific PCR whether MART-1
promoters were differentially methylated primer sequences
(Supplementary Table S4 online). The results showed that MEL-
XY1 CCs had a much higher degree of promoter methylation
than MEL-XY3 CCs, both at 7- and 14-day growth (Table 1).
Interestingly, when the promoter methylation status was
compared between colonies of 7 and 14 days, no differences
were found, although the IHC and FACS results showed less
expression of MART-1 for both cell lines. Therefore, some other
factors might be operating to regulate MART-1 expression at
longer growth times. For gp100, no significant differences were
found between MEL-XY1 CC and MEL-XY3 CC methylation
levels in two different promoter regions (data not shown).
Lysis of CCs by MD-Ag-specific CTLs
We next investigated whether CCs were susceptible to lysis
by CTLs, as they could have intrinsic mechanisms of resis-
tance. First, we assayed the lytic effect of two specific CTL
clones, anti-MART-1 (M27) and anti-gp100 (G154; Yee et al.,
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Figure 4. Analysis of MART-1 and gp100 expression in melanoma clones (in time). FACS analysis of MART-1 and gp100 expression in selected clones
(with low, medium, and high expression) tested at different growth times (a). Clonogenic index (%) determination for each clone at first and last FACS
determination (b). ns, no significant differences were found (t-test, P40.05).
Table 1. qMSP analysis of MART-1 promoter on
clonogenic cells
Samples Ratio
(7 Days) MEL-XY1 CC/(7 days) MEL-XY3 CC1 3985.18±0.73
(14 Days) MEL-XY1 CC/(14 days) MEL-XY3 CC1 4715.68±0.41
(14 Days) MEL-XY1 CC/(7 days) MEL-XY1 CC2 1.32±0.74
(14 Days) MEL-XY3 CC/(7 days) MEL-XY3 CC2 1.12±0.40
Abbreviations: CC, clonogenic cell; qMSP, quantitative methylation-
specific PCR.
1Ratio of promoter methylation levels between MEL-XY1 CC and
MEL-XY3 CC of 7-days or 14-days as indicated.
2Ratio of promoter methylation levels between MEL-XY1 CC and
MEL-XY3 CC of 7-days or 14-days as indicated. Ratios are expressed as
mean±SD.
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2002), on MEL-XY3 cells (MART-1þ /gp100þ //HLA-A0201þ ,
Figure 5a). After co-incubation with CTL, lysis was deter-
mined by the clonogenic assay. Both clones efficiently lysed
MEL-XY3 cells abolishing colony formation, although G154
clone appeared to be more efficient (Figure 5b). When clones
were combined, total lysis approached 90–100% of the cells.
Thus, MEL-XY3 CCs were not intrinsically resistant to specific
CTL lysis.
Further, we assayed lysis by CTLs on MEL-XY1 cells, as we
could differentiate lysis of MD-Ag-expressing from that of
MD-Ag-non-expressing cells; 98% of 7-day CCs and the cell
line expressed HLA-A0201 (Figure 5a). Lysis on the cell line
and CCs by M27 and G154 CTL at a 5:1 (effector:target cells)
ratio was calculated by Trypan blue exclusion and MD-Ag
expression was determined by immunocytochemistry on the
surviving cells. We found that 50% of CCs were lysed by M27
clone, 30% by G154 clone, and 70% when both clones
functioned together (Figure 5c). The same trend was observed
for the MEL-XY1 cell line (Figure 5c). As a negative control,
MEL-XY2 (MART-1/gp100//HLA-A0201; Figure 5a) cell
line showed only marginal lysis (Figure 5c). Analysis of
MART-1/gp100 expression in CCs before and after treatment
with both CTL clones revealed that only 0.3% of surviving
cells expressed these MD-Ag (Figure 5d and e). Therefore,
MART-1/gp100-expressing CCs were lysed by specific CTLs,
whereas Ag-non-expressing CCs were not.
DISCUSSION
In this paper, we investigated whether the expression of
MART-1/gp100 affects replicative or clonogenic potential of
CM cells, and whether CCs were susceptible to lysis by
specific CTL clones. We analyzed the MD-Ag status of proli-
ferative populations in CM primary biopsies and metastases.
A pattern of MD-Ag heterogeneity was observed, and no
differences in proliferative indexes of MD-Ag-expressing and
-non-expressing populations were found. Thus, other factors
determine the fitness and prevalence of MART-1/gp100-
expressing or -non-expressing sub-populations. In addition,
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Figure 5. Lysis of melanoma cells by MART-1- and gp100-specific cytotoxic T lymphocyte (CTL) clones. (a) HLA-A0201 FACS analysis on MEL-XY3,
MEL-XY1, MEL-XY2 cell lines, and MEL-XY1 7-day clonogenic cells (CCs). Filled histogram: isotype-matched control. (b) Target cells (MEL-XY3) were
incubated overnight with effector CTL clones (M27: anti-MART-1 and/or G154: anti-gp100) as indicated, and lysis was determined by colony inhibition (%).
Individual experiments (I, II) and mean results (III) are shown. (c) Target cells (MEL-XY1, MEL-XY1 CC) were incubated with CTL clones (effector:target cells, 5:1),
and cell lysis was determined by Trypan blue exclusion (%; mean±SD of two experiments). (d) MART-1/gp100 expression in surviving cells (mean±SD of
10 high-power field). *t-test, Po0,05. (e) Representative pictures of MEL-XY1 CCs after incubation without (top) or with (bottom) CTL clones. Bar¼ 10mm.
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the expression of MD-Ag would not be related to CM
metastatic ability, as primary tumors and metastases had
similar distribution of sub-populations. It should be stressed
that replicative and clonogenic abilities are not equal. A
replicating cell may be clonogenic, capable of originating
several thousands of descendent cells, or be a differentiation-
committed cell, only able to execute a few divisions, and
then terminally differentiate. These hierarchically different
cell types could not be disclosed in biopsies, in which we
measured proliferation by Ki-67 staining. We therefore
studied MD-Ag expression in in vitro-developed colonies of
two cell lines at two growth stages. For MEL-XY1, we found
that 7-day colonies presented a heterogeneous MD-Ag
expression pattern, with positive, negative, and mixed
expression. The 14-day colonies attained different sizes,
some with thousand cells; therefore, even within CCs,
differential clonogenic potential exists, and the heteroge-
neous expression pattern was conserved. The existence of
mixed-pattern colonies is difficult to explain. MEL-XY1 has
not been cloned, and as MD-Ag-expressing and -non-
expressing cells coexisted in the original tumor, it could be
that colonies differentially expressing MD-Ag reflect the
characteristics of the originating CCs. In an attempt to explain
such heterogeneity, we analyzed MEL-XY1 clones for
MART-1 and gp100 expression, expecting to find double-
expressing, double-non-expressing, and heterogeneous
clones. Instead, in every clone analyzed, we found different
levels of MD-Ag expression, without correlation in MART-1
and gp100 expression levels, unlike described in melano-
cytes (Hoashi et al., 2005). We even found that some clones
varied MD-Ag expression with time, which might contribute
to explain the heterogeneous pattern of colonies, although
retaining similar clonogenic ability. These results further
support MART-1 and gp100 plasticity as a source of
heterogeneity and independence of proliferative status in
melanoma. For MEL-XY3, 7-day colonies expressed MART-1/
gp100 uniformly. Interestingly, similar changes in Ag
distribution were observed after 14 days of growth. The same
variable expression pattern was observed for tyrosinase.
MD-Ag-coding genes could be inactivated in cells of the
same colony by epigenetic changes. A previous work studied
20 cutaneous and ocular melanoma cell lines and found
a correlation between promoter methylation and protein
expression; however, once a cell line did not express MART-
1, it would not recover its expression (van Dinten et al.,
2005). This observation is quite different from ours, when we
essentially observed a rapid transition between cells expres-
sing and not expressing MART-1. Mart-1 promoter methyla-
tion levels in MEL-XY1 CCs were higher than that in MEL-XY3
CC. However, given the difference in MART-1 expression at
14 days of growth, and as gene methylation remained
constant, it would appear that other mechanisms, such as
hypoxia, might contribute to the regulation of Ag expression.
It was of interest to study the expression of a putative
melanoma stem cell marker such as CD271 in colonies
(Boiko et al., 2010; Civenni et al., 2011). We found in our
experimental conditions a low percentage of cells with
membrane expression as reported, and, surprisingly, intense
cytoplasmatic expression. MEL-XY1 7-day colonies showed a
heterogeneous CD271 pattern, whereas MEL-XY3 colonies
expressed CD271 homogenously, and both showed Ag
downregulation by 14 days. The lack of membrane expres-
sion in CCs is unexpected and shall be further studied.
With respect to CC susceptibility to lysis by specific CTLs,
we showed that MART-1/gp100-expressing CCs, as detected
by IHC, were efficiently killed. We used Trypan blue
exclusion and clonogenic assays to address the efficiency of
CC lysis. The latter method was recently referred to be more
sensitive for assessing cytotoxicity than the chromium-release
assay (Williams et al., 2010). Our results support the fact that
CCs expressing the proper Ag and HLA-class-I haplotype
would not be intrinsically resistant to lysis by CTLs. The fact
that MART-1/gp100-non-expressing cells were not lysed in
this system would preclude any bystander effect, as suggested
in other experimental systems (Breart et al., 2008). This is
an important issue, as most of the CTL clones used in
immunotherapy, either derived from tumor infiltrating lym-
phocytes (Maeurer et al., 1996; Benlalam et al., 2007;
Rosenberg and Dudley, 2009) or from genetically engineered
peripheral lymphocytes, are directed against these MD-Ag
(Johnson et al., 2009; Peng et al., 2009).
Our study is relevant for immune-targeted therapies in
human CM, as we have demonstrated that MART-1 and
gp100 expression is not related to proliferation or clonogenic
potential of CM cells. As MD-Ag-expressing and -non-
expressing cells are proliferative and clonogenic, giving rise
to colonies of thousand cells, both sub-populations should be
taken into consideration as targets to eradicate tumors, even if
these Ag are not expressed in putative melanoma-initiating
cells (Boiko et al., 2010). Clinical responses to ipilimumab,
which augments CTL activity, suggest that, on the effector
side, a mid-avidity naı¨ve CTL repertoire (Ueno et al., 2004;
Schmid et al., 2010) may provide an efficient antitumor
response. It was recently reported that BRAF inhibitor
PLX4032 upregulates MART-1, gp100, Tyrp-1, and Tyrp-2
expression without affecting CTL function, allowing im-
proved recognition of melanoma cells by specific immune
effectors (Boni et al., 2010). In the case of vaccine adjuvant
therapy, the findings reported in this paper stress the
convenience of addressing multi-antigenic targets to boost
immunity against the different cell populations comprising
the tumor (Barrio et al., 2006; von Euw et al., 2008).
MATERIALS AND METHODS
Cell lines
The human CM cell lines MEL-XY1, MEL-XY2, and MEL-XY3 were
previously described (von Euw et al., 2007) and periodically tested
to be mycoplasm free.
Colony formation assay and purification
Exponentially growing cells, dissociated with 5mM EDTA, were
resuspended in culture medium with 1.5% methylcellulose (Sigma,
St Louis, MO), plated at 500 cells per cm2 over a 0.5% agar
underlayer, and incubated for 7 or 14 days. To obtain isolated CCs,
colonies were recovered by filtration through a 40-mm Cell Strainer
(BD Biosciences, San Jose, CA) and dissociated with EDTA. For IHC,
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colonies were purified without filtration and pellets were paraffin
embedded. For isolation of clones, individual colonies were picked
under the microscope, disaggregated with trypsin/EDTA, and
cultured in adherent plates. Clones were expanded for testing
MART-1 and gp100 expression by FACS and clonogenic assays.
Some selected clones were retested on confluence.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue/colony sections (4mm) were
stained using the following primary mouse anti-human monoclonal
antibodies: Ki-67 (clone MIB-1, Dako, Glostrup, Denmark), MART-1
(clone A103, Dako), gp100 (clone HMB45, Dako), tyrosinase (clone
T311, Santa Cruz Biotechnology, Santa Cruz, CA), CD271 (clone c40-
1457, BD Biosciences). Antigens were revealed with 3,3’-diamino-
benzidine. For simultaneous detection of MART-1/gp100 and Ki-67,
incubation with Ki-67 was first performed and revealed with 3,3’-
diaminobenzidine, and MART-1 and gp100 antibodies were later
incubated and revealed with Liquid Permanent Red (Dako).
FACS analysis
HLA-A0201 (clone BB7.2, BD) and CD271 membrane expression was
assessed using monoclonal antibodies on viable CM cells. MART-1,
gp100, and CD271 intracellular expression was assessed after cell
permeabilization. Isotype controls and unconjugated antibodies were
revealed with RPE Goat anti-mouse F(ab’)2 (Dako). Apoptosis and
necrosis were assessed by Annexin-V and Propidium iodide binding
(BD Biosciences) and FACS analysis (FACSCalibur, BD Biosciences)
performed with the CELLQuest software (BD Biosciences).
Lysis of melanoma cells by CTL clones in vitro
CTL clone effector cells specific for MART-1 (M27: AAGIGILTV) and
gp100 (G154: KTWGQYWQV), HLA-A0201 restricted (Yee et al.,
2002) were expanded as described (von Euw et al., 2007). To
determine lysis, CTL (effector) and target CM cells were incubated
overnight at different ratios in AIMV medium (Invitrogen, Grand
Island, NY). Thereafter, cells were recovered for immunocytochem-
istry analysis, assessed by Trypan blue exclusion, or plated for the
clonogenic assay (quadruplicate). Colony formation was assessed at
7 and 14 days. Colony inhibition (%) was calculated referring to
control target cells (0%).
See also Supplementary Materials and Methods online.
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